Lessons for pharmacogenomics studies: Association study between CYP2D6 genotype and tamoxifen response

Pharmacogenetics and Genomics

Volumn 20, Issue 9, 2010, Pages 565-568

  Kiyotani, Kazuma ^a   Mushiroda, Taisei ^a   Hosono, Naoya ^b   Tsunoda, Tatsuhiko ^b   Kubo, Michiaki ^b   Aki, Fuminori ^c   Okazaki, Yutaka ^d   Hirata, Koichi ^e   Takatsuka, Yuichi ^f   Okazaki, Minoru ^g   Ohsumi, Shozo ^h   Yamakawa, Takashi ⁱ   Sasa, Mitsunori ^j   Nakamura, Yusuke ^a   Zembutsu, Hitoshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b RIKEN   (Japan)

^c Itoh Surgery and Breast Clinic ^*  (Japan)

^d Shin Sapporo Breast Clinic   (Japan)

^e SAPPORO MEDICAL UNIVERSITY   (Japan)

^f KANSAI ROSAI HOSPITAL   (Japan)

^g Sapporo Breast Surgical Clinic   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

ⁱ Department of Surgery   (India)

^j Tokushima Breast Care Clinic   (Japan)

more..

Author keywords

breast cancer; chemotherapy; concomitant treatment; CYP2D6; endoxifen; monotherapy; P450 2D6; tamoxifen

Indexed keywords

CYTOCHROME P450 2D6; TAMOXIFEN;

ALLELE; ARTICLE; BREAST CANCER; CANCER RECURRENCE; DISEASE FREE SURVIVAL; GENE FREQUENCY; GENOTYPE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PHARMACOGENOMICS; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 77955924464     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833af231     Document Type: Article

References (10)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-1717.
2. Kiyotani K, Mushiroda T, Sasa M, Bando Y, Sumitomo I, Hosono N, et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 2008; 99:995-999.
3. Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 2010; 28:1287-1293.
4. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23:9312-9318.
5. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009; 302:1429-1436.
6. Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, Sweeney C, et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005; 91:249-258.
7. Okishiro M, Taguchi T, Jin Kim S, Shimazu K, Tamaki Y, Noguchi S. Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer 2009; 115:952-961.
8. Lash TL, Lien EA, Sorensen HT, Hamilton-Dutoit S. Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 2009; 10:825-833.
9. Hosono N, Kato M, Kiyotani K, Mushiroda T, Takata S, Sato H, et al. CYP2D6 genotyping for functional-gene dosage analysis by allele copy number detection. Clin Chem 2009; 55:1546-1554.
10. Newman WG, Hadfield KD, Latif A, Roberts SA, Shenton A, McHague C, et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res 2008; 14:5913-5918.